



Company Contact – Jim Dorsey
BioClinica, Inc.
267-757-3040

Investor Contact – Linda Decker
Financial Media – Bill Gordon
Porter, LeVay & Rose, Inc.
212-564-4700

Trade Media Contact – Brian Gawron
Diccicco Battista Communications
215-957-0300

FOR IMMEDIATE RELEASE

**BIOCLINICA™ ACQUIRES CARDIONOW FROM AGFA HEALTHCARE
-Adds Proven Solution for Secure, Regulatory Compliant Electronic Transmission and Analysis of
Medical Images for Clinical Trials-**

NEWTOWN, PA, September 1, 2009 – BioClinica, Inc., (NASDAQ: BIOC), a global provider of clinical trial services, today announced that it has acquired the CardioNow unit of Agfa HealthCare. With this addition, BioClinica now offers streamlined electronic transport solutions to facilitate the blinding, sharing, tracking and archiving of medical images for multi-center clinical trials as part of its suite of imaging services. Imaging information will also be integrated with BioClinica Express electronic data capture to further simplify and enhance the clinical trial process for life science companies.

Since 1999, CardioNow has provided core labs, investigator sites, and medical device and pharmaceutical companies with an established and proven web-based system for the secure, regulatory compliant transmission and analysis of medical images that are integral components of clinical trials. The solution is also extensively utilized by remote independent reviewers for online case review and quantitative analysis, clinical event adjudication, and data safety monitoring. Over the past 10 years, CardioNow has successfully managed more than 8.8 million DICOM (Digital Imaging and Communications in Medicine) images for clinical studies worldwide.

With the integration of CardioNow, BioClinica will be able to manage every step of the process that begins once a medical image is acquired at a clinical site through the delivery of evaluated results to the sponsor. This end-to-end control will ensure that the process is as efficient and expedient as possible.

“CardioNow fits perfectly into BioClinica’s strategy of adding components that are both complimentary to our current products and services and that help to create a more efficient clinical trial process. We will continue to build on the superior technology and high level of customer service offered by Agfa Healthcare’s CardioNow unit,” said Mark Weinstein, President and CEO of BioClinica. “An additional benefit is that once CardioNow is integrated with our current processes -- approximately 45 days -- we can offer our clients an immediate cost savings on each of the more than 200 clinical trials that we are currently supporting.”

“A leading solution like CardioNow is well suited to support the ongoing expansion of BioClinica’s extensive global clinical trial services portfolio,” said Eric Maurincomme, Chief Strategy & Marketing Officer of Agfa HealthCare. “We are convinced that the CardioNow business will continue to flourish within BioClinica, and are working closely together to enable a smooth transition.”

Mr. Weinstein concluded, “CardioNow will provide immediate benefits to our Bioimaging Services clients and as such the CardioNow team will be integrated into that division and report to Dave Pitler, president of our Bio-Imaging Services division. We will immediately begin work on integrating the CardioNow products and services with our eclinical offering to provide medical device and pharmaceutical clients with a comprehensive offering that will be unmatched in the industry.”

-more-

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of clinical trials services, helping to support drug and product development efforts through all phases of the clinical trial process. Created from the acquisition of Phoenix Data Systems, Inc. by Bio-Imaging Technologies, Inc., BioClinica offers industry-leading medical image management and best-of-breed electronic data capture to companies in the life sciences industry. In addition, BioClinica offers solutions that combine these core services to maximize efficiency and manageability throughout the entire clinical development process. With more than 2,000 successful trials, BioClinica is unsurpassed in its knowledge and experience, helping bring many of today's drugs from early phase development through final approval. BioClinica operates two state-of-the-art, FDA-compliant core labs in the United States and Europe, with business offices in the United States, France, Germany, United Kingdom and the Netherlands. For more information, please visit www.bioclinica.com.

About Agfa Healthcare

Agfa HealthCare, a member of the Agfa-Gevaert Group, is a leading provider of IT-enabled clinical workflow and diagnostic image management solutions, and state-of-the-art systems for capturing and processing images in hospitals and healthcare facilities. Agfa HealthCare has over a century of healthcare experience related to diagnostic imaging and has been a pioneer in the healthcare IT market since the early 1990's. The business group has sales offices and agents in over 100 markets worldwide. Sales for Agfa HealthCare in 2008 were 1,223 million Euro. For more information, please visit www.agfahealthcare.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

#####